Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec helped patients achieve significantly more time in target blood glucose range (Time in Range) vs once-daily basal insulin glargine U100 in ONWARDS 11In the ONWARDS 1 and 3 trials, more people achieved blood glucose targets without clinically significant or severe hypoglycaemia with once-weekly basal insulin icodec vs once-daily basal insulin
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative insulin icodec.